Agomab Therapeutics

Agomab Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of growth factor modulating candidates to treat fibro-inflammatory diseases. The company's lead programs include ontunisertib, an oral small molecule inhibitor for fibrostenosing Crohn’s disease, and AGMB-447, an inhaled lung-restricted inhibitor for idiopathic pulmonary fibrosis. Its therapeutic approach focuses on restoring organ function by targeting growth factor biology to regenerate damaged tissues.